Journal
JOURNAL OF VIROLOGY
Volume 79, Issue 21, Pages 13797-13799Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.79.21.13797-13799.2005
Keywords
-
Categories
Funding
- NCI NIH HHS [CA82055, R01 CA082055] Funding Source: Medline
- NIAID NIH HHS [AI50123, R01 AI050123] Funding Source: Medline
- NICHD NIH HHS [P01 HD011149] Funding Source: Medline
Ask authors/readers for more resources
The increased transmission and geographic spread of dengue fever (DF) and its more severe presentation, dengue hemorrhagic fever (DHF), make it the most important mosquito-borne viral disease of humans (50 to 100 million infections/year) (World Health Organization, Fact sheet 117, 2002). There are no vaccines or treatment for DF or DHF because there are no animal or other models of human disease; even higher primates do not show symptoms after infection (W. F. Scherer, P. K. Russell, L. Rosen, J. Casals, and R. W. Dickerman, Am. J. Trop. Med. Hyg. 27:590-599, 1978). We demonstrate that nonobese diabetic/severely compromised immunodeficient (NOD/SCID) mice xenografted with human CD34(+) cells develop clinical signs of DF as in humans (fever, rash, and thrombocytopenia), when infected in a manner mimicking mosquito transmission (dose and mode). These results suggest this is a valuable model with which to study pathogenesis and test antidengue products.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available